ININGIZIMU Afrika sekuseduze ukuthi ikhiqize imishanguzo yokugomela igciwane leHIV ewumjovo engambi eqolo. Inkampani ekhiqiza imithi iCipla yase-India, iqinisekise lokhu emithonjeni yezindaba yase-United Kingdom ngoLwesihlanu. Ngesikhathi kuvela ukuthi sekuzoba nemishanguzo ewumjovo enciphisa ingozi yokuthi umuntu oya ocansini nomuntu onaleli gciwane atheleleke, kwaba nokukhathazeka mayelana nokuthi amazwe asathuthuka ngeke akwazi ukuwuthenga lowo mjovo ngoba umba eqolo. Kwavela nokuthi izinkampani ezinye ngeke zikwazi ukuzikhiqizela umjovo ongambi eqolo oyifuzamuthi (generic) ngoba ilungelo lalo mjovo ngelabasunguli bawo okuyiViiV Healthcare. Inhlangano iWorld Health Organisation (WHO) yathi izozama ukuthi abasunguli balo mjovo banikeze izinkampani zasemazweni angu-90 athwele kanzima, kuwo okubalwa neNingizimu Afrika, ukuze imiphakathi ehlala kula mazwe ikwazi ukuthola leli thuba. Lo mjovo iCabotegravir (CAB-LA), owenza okufana ncamashi nalowo obizayo ozobe ukhiqizwa emazweni angomacaphuna kusale, kuleli uzokhiqizwa inkampani iCipla eseThekwini naseBenoni. ICabotegravir engumjovo, kuvele ukuthi isebenza kangcono kunamapilisi aziwa ngePre-exposure Prophylaxis (PrEP), asetshenziswayo kuleli. Umjovo ongelona ifuzamuthi ungabiza ngaphezulu kukaR5 000 okuyimali iNingizimu Afrika engeke ikwazi ukuyikhokha ukuze ithengele abantu bakuleli abafuna ukuzivikela.